FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

SkyePharma cuts plant staff by a third; Dr Reddy's forecasts 10% sales growth;


Free newsletter via e-mail
Tools

> SkyePharma said it plans to cut its 120-strong workforce at a manufacturing plant in Lyon, France, by one-third, following a 10 percent reduction of the staffing at its R&D facility in Muttenz, Switzerland. Release

> Plans by Europe's biggest drugs distributor, Celesio, to set up a pharmacy chain in its home market of Germany hinge on a European court ruling on Tuesday. Report

> Indian drug maker Dr. Reddy's Laboratories expects revenue growth of 10 percent in the fiscal year to March 2010 because of new product launches, its chief executive officer said. Report

> Cell Therapeutics said it's closing its operations in Bresso, Italy, and has reached agreement with the employee union there regarding a severance package for 56 people. Report

> GlaxoSmithKline took another step to bolster its early-stage pipeline of cancer drugs by signing a deal worth up to $370 million with privately held British biotech group Oxford BioTherapeutics. Release l Report

> Japan's Takeda Pharmaceutical has signed a deal to snap up IDM Pharma for $2.64 a share, or about $70 million. Report

> Xconomy reports that GlaxoSmithKline has spun-off Tempero Pharmaceuticals from GSK's Immuno-Inflammation Centre of Excellence in Drug Discovery. Report

> New York City council members, Senator Tom Duane (D-NY) and Assemblyman Mark Weprin (D-NY) are urging legislators to back a bill that would offer $3 million a year in tax breaks. Report

> The once high-flying diagnostic company Nanogen has filed for Chapter 11 bankruptcy protection, saying that it plans to sell off almost all its assets to French company Elitech Group for $25.7 million. Report

> Less than a month after announcing an $8 million closing, San Diego, CA-based start-up Anaphore has pulled in another $13 million and three new investors. Report

> GlobeImmune will receive $40 million up front in a deal with Celgene that could be worth up to $500 million. The two companies have entered into a worldwide strategic collaboration for the discovery, development and commercialization of cancer therapies. Report

And Finally... Taking a DHEA supplement combined with vitamin D and calcium can significantly improve spinal bone density in older women, a new study found. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Comments (1) | Post a comment
More stories about Dr. Reddy's Laboratories   pharmaceutical layoffs  

Comments

the beneifts of vitamin D keep rolling in. If you want to see some good summaries take a look at www.vitaminD3world.com The site also has a good newsletter worth signing up for

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.